Browsing Tag
IKT
1 post
Why Inhibikase Therapeutics (NASDAQ: IKT) is tapping public markets now for $100m in new funding
Find out how Inhibikase Therapeutics plans to use its $100M equity raise to fund pipeline trials and what it means for shareholders in 2025.